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Background: Dietary supplementation with oligosaccharides has been proven to be beneficial for health in several
mammalian species. Next to prebiotic effects resulting in a modulation of gut micro biota, immunomodulatory
effects of oligosaccharides have been documented in vivo. Supplementation with defined oligosaccharide fractions
has been shown to attenuate allergic responses and enhance defensive immune responses. Despite the
accumulating evidence for immunomodulatory effects, very limited information is available regarding the direct
mechanism of action of oligosaccharides. This study aims to elucidate the effects of selected oligosaccharide
fractions on the lipopolysaccharide (LPS) induced inflammatory response in equine peripheral blood mononuclear
cells (PBMCs). We investigated three different products containing either galacto-oligosaccharides (GOS) alone, a
combination of GOS with fructo-oligosaccharides (FOS), and a triple combination of GOS and FOS with acidic
oligosaccharides (AOS), at different concentrations. These products have been used in an identical composition in
various previously published in vivo experiments. As the selected oligosaccharide fractions were derived from
natural products, the fractions contained defined amounts of mono- and disaccharides and minor amounts of
endotoxin, which was taken into account in the design of the study and the analysis of data. Acquired data were
analysed in a Bayesian hierarchical linear regression model, accounting for variation between horses.
Results: Exposing cultured PBMCs to either GOS or GOS/FOS fractions resulted in a substantial dose-dependent
increase of tumour necrosis factor-α (TNF-α) production in LPS challenged PBMCs. In contrast, incubation with
GOS/FOS/AOS resulted in a dose-dependent reduction of both TNF-α and interleukin-10 production following LPS
challenge. In addition, incubation with GOS/FOS/AOS significantly increased the apparent PBMC viability, indicating
a protective or mitogenic effect. Furthermore, mono- and disaccharide control fractions significantly stimulated the
inflammatory response in LPS challenged PBMCs as well, though to a lesser extent than GOS and GOS/FOS
fractions.
Conclusions: We found distinct immunomodulating effects of the investigated standardised oligosaccharide
fractions, which either stimulated or suppressed the LPS induced inflammatory response in PBMCs. Both scenarios
require additional investigation, to elucidate underlying modulatory mechanisms, and to translate this knowledge
into the clinical application of oligosaccharide supplements in foals and other neonates.
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During the past decade, numerous in vivo studies in
humans (and experimental animals) have reported
beneficial effects of dietary supplementation with oligo-
saccharides derived from natural products such as milk,
fruits and vegetables. The original goal of supplemen-
ting infant formulas with oligosaccharide fractions was
to mimic prebiotic effects of human milk oligosaccha-
rides in non-breastfed infants. Several oligosaccharide
fractions were synthesised as possible surrogates of human
milk oligosaccharides. Short chain galacto-oligosaccha-
rides (GOS) are oligomers of lactose (degree of polyme-
rization (dp) 2–6), produced by elongating lactose using
β-galactosidase enzymes [1]. GOS is applied either alone
or in combination with long-chain fructo-oligosaccharides
(FOS), using a GOS:FOS ratio of 9:1. FOS fractions are
acquired by removing the short-chain fructans from
chicory inulin, resulting in fructan mixtures with terminal
glucose monomers and a minimal dp of 22 [1]. During the
last few years, additions of methylated pectin- derived
acidic oligosaccharides (AOS) to infant formulas were
investigated as well, mostly combined with both GOS
and FOS (GOS:FOS:AOS ratio of 9:1:2) [1]. The prebiotic
properties of these commercially produced GOS/FOS
and GOS/FOS/AOS fractions have been proven in various
studies [2-5].
Moreover, immunomodulatory properties of GOS and
combinations of both GOS/FOS and GOS/FOS/AOS
have been documented in vivo. Dietary supplementation
with these oligosaccharide fractions was shown to be
beneficial for both allergic immune responses [6-10] and
defensive immune responses following viral or bacterial
challenge [11-13]. Furthermore, there is evidence that
early supplementation with GOS/FOS (with or without
AOS) lowers the incidence of infections in human infants
[14,15]. In most of these studies, the effects of oligosaccha-
rides on the intestinal microbiotica were discussed as
the primary mode of action of the administered oligosac-
charides. In contrast, very limited information is available
concerning any direct immunomodulatory effects of these
oligosaccharide fractions and the underlying mechanisms.
Eiwegger et al. [16] reported that human milk-derived
oligosaccharides and plant-derived oligosaccharides (low-
molecular-weight fucoidan) affect the cytokine production
and activation of unchallenged cord blood derived T cells
in vitro. In a more recent study by the same group, the
in vitro incubation of unchallenged human cord blood
mononuclear cells with low concentrations (10–100 μg/
ml) of AOS or GOS combined with FOS did not result in
an alteration of cytokine production, whereas incubation
with similar concentrations of acidic human milk-derived
oligosaccharides did significantly induce the production of
interferon-γ and interleukin-10 [17]. The latter study also
provides in vitro evidence for epithelial transport ofprebiotic oligosaccharides, enabling direct contact be-
tween oligosaccharides and cells of the immune system.
Neonatal foals possess limited defence mechanisms, in
particular due to the impermeability of the equine pla-
centa to maternal immunoglobulins. Consequently, new-
born foals are strongly dependent on the transfer of
immunoglobulins through the uptake of colostrum [18].
Moreover, similar to newborns of other mammalian
species, both innate and adaptive immune responses
are immature at the time of delivery [19]. Dietary sup-
plementation of oligosaccharides would be one of the
possible options to improve the development of the
immune system and consequently lower the incidence
of infections in foals, which are often life-threatening.
However, up to now no research has been published
regarding immunomodulatory effects of oligosaccharides
in the horse, neither in vivo nor in vitro.
In this study, we investigated the effects of defined
oligosaccharide fractions on the inflammatory response
in equine peripheral blood mononuclear cells (PBMCs)
following a standardised lipopolysaccharide (LPS) chal-
lenge. We chose to use equine PBMCs as a readily
available representative model of immune cells in this
animal species.
Methods
Animals and sample collection
Twelve healthy, adult, Dutch warm blood horses (K.W.P.
N. studbook) were sampled in total during this study.
PBMCs from five horses were used for experiments with
oligosaccharide fractions, four horses were sampled for
control experiments with glucose/lactose solutions, and
PBMCs of three horses were used for cell viability assays.
Experiments could not all be executed in the same
horses, due to the large amounts of PBMCs required to
investigate all fractions and concentrations in triplicate
(at least). Adult horses had to be used as blood donors,
as large volumes of blood were needed to isolate suffi-
cient amounts of PBMCs for these first explorative
experiments in the horse; withdrawing larger volumes of
blood from neonatal foals is restricted by ethical con-
cerns. From each horse, 250 ml of blood was collected
by jugular venipuncture directly into sterile heparinised
blood collection tubesa. Blood samples were kept cooled
and PBMC isolation was started within 1 hour after col-
lection. All experimental procedures were approved by
the committee of ethical considerations regarding animal
experiments of Utrecht University (DEC Utrecht).
PBMC isolation
Blood samples were diluted 1:1 in sterile PBSb containing
2 mM EDTAc and subsequently layered over Ficoll-
Paque™ plusd. After centrifugation (400× g, 30 minutes at
room temperature), PBMCs were pipetted from the Ficoll
Table 1 Composition of the applied oligosaccharide
fractions and glucose/lactose controls
(per 10 ml of medium)
Incubation Oligosaccharides Glucose Lactose
GOS 2% 200 mg GOS 62.22 mg 71.11 mg
GOS/FOS 2% 180 mg GOS, 20 mg FOS
(+0.73 mg maltodextrin)
56.00 mg 64.00 mg
GOS/FOS/AOS
2%
150 mg GOS, 16.67 mg FOS
(+0.60 mg maltodextrin),
33.33 mg AOS
46.67 mg
(+2.83 mg
monomers)
53.33 mg
glucose/lactose,
corresponding
with GOS 2%
- 62.22 mg 71.11 mg
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resuspended in RPMI 1640 Mediumb supplemented with
2 mM glutamineb, 100 IU/ml penicillinb, 100 μg/ml
streptomycinb, and 10% horse serum (prepared in our
own laboratory according to standard procedures).
PBMCs were counted using trypan blue and resus-
pended to a density of 4*106 cells/ml medium. Follow-
ing storage overnight at 4°C to attenuate possible
stimulatory effects of the applied Ficoll, PBMCs were
seeded in 24 well plates at a density of 4*106 cells/ml
medium/well.
Cell culture experiments
After seeding the PBMCs in 24 well plates, the plates
were incubated for 2 hours at 37°C and 5% CO2. After
this, the plates were centrifuged for 10 minutes at 400×
g before refreshing the medium without removing
PBMCs. The experiments were started by pre-incubating
the PBMCs for 2 hours with supplemented RPMI con-
taining different concentrations of oligosaccharide frac-
tions (including blank controls, i.e. supplemented RPMI
without extra additions). After pre-incubation, plates
were centrifuged again and the medium was replaced
with medium containing 0 or 1 μg/ml LPS (Escherichia
coli O111:B4)c combined with different concentrations
of oligosaccharide fractions (including blank controls).
Plates were placed in the incubator for another 4 hours,
after which samples for ELISA were collected and stored
at −80°C. Thus, there was a total incubation time of
6 hours for all investigated conditions. All different incu-
bations were performed in triplicate or in quadruplicate
for each horse. Additional experiments were performed
following the same protocol with different concentra-
tions of glucose and lactose, to account for the fact that
the oligosaccharide fractions- especially GOS- contain
considerable amounts of these mono- and disaccharides.
We investigated the effects of three different stan-
dardised oligosaccharide fractions with known immuno-
modulatory properties in vivo, using oligosaccharide
concentrations ranging from 0.5% to 2.0%. The exact
composition of all 2% incubations is summarized in
Table 1 (1% and 0.5% solutions were obtained by dilut-
ing 1:1 in supplemented RPMI). The applied GOS
fraction (Vivinal GOS syrupe, dp 2–6) consisted of
approximately 45% GOS, 14% glucose, 16% lactose and
25% water. GOS was investigated separately, combined
with FOS (Raftiline HPf, dp ≥ 23, approximately 96.5%
FOS and 3.5% maltodextrine) in a 9:1 ratio, and com-
bined with both FOS and AOSg (dp 1–20, approximately
85.5% AOS, 7.25% monomers and 7.25% moisture) in a
9:1:2 ratio. Ratio’s and diluting factors were based on
oligosaccharide contents of the used products. Thus, all
2% oligosaccharide solutions contained 20 mg/ml oligo-
saccharides and, in addition, defined amounts of mono-and disaccharides. The control incubations with glucosec
and lactosec were chosen to correspond with the glucose
and lactose concentrations of the GOS fraction, as this
was the oligosaccharide fraction with the highest con-
centrations of mono- and disaccharides (see Table 1).
The effects of glucose/lactose controls were investigated
to eventually discriminate between effects of the oligo-
saccharide preparations and possible effects of glucose
and lactose, which are present in the oligosaccharide
fractions as well. All experiments in this study were
performed using the same batch of GOS, FOS and AOS,
of which the composition was analysed and stated by the
manufacturers.
ELISA
Protein levels of tumour necrosis factor-α (TNF-α) and
interleukin-10 (IL-10) were measured by means of ELISA
on the cell culture supernatants, using Duo set® ELISA
Development System for equine TNF-α and equine IL-
10h. Standard operating procedures of the manufacturer
were followed, applying all required buffers and solutions
in the form provided by the manufacturerh. The detection
limits of the ELISAs were 15.625 pg/ml (TNF-α) and
156.25 pg/ml (IL-10), respectively.
Cell viability assessment
To investigate possible influence of the applied incubation
mixtures on cell viability, CCK-8c viability assays were
performed according to manufacturer’s instructionsc. Prior
to viability assessment, cell culture experiments were
carried out identical to the experiments which are de-
scribed above, with the exception that cells were seeded
and incubated in 96 well plates (at a density of 8*105 cells/
200 μl/well, similar to experiments in terms of cells per ml
medium and cm2 surface).
Endotoxin assay
All applied solutions (as described in Table 1) were
tested for endotoxin contamination using a Limulus
Ambocyte Lysate endotoxin assay according to manu-
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(determining the range of detection) ranged from 0.1-1
Endotoxin Unit (EU)/ml.
Data analysis and statistical methods
Data were analysed by means of Bayesian hierarchical
linear regression, assuming a normal distribution of the
log-transformed ELISA data. A hierarchical approach
was taken to account for variation between horses.
PBMC responses were allowed to vary between horses
with regard to general PBMC reactivity (random inter-
cept), and PBMC reactivity specifically against incuba-
tion with LPS, GOS, FOS, and AOS (random slopes).
Analyses were performed in a Bayesian framework, using
JAGS, a program for analysis of Bayesian models using
Markov Chain Monte Carlo (MCMC) simulation (ver-
sion 3.2.0) [20]. Simulations in JAGS were set up and
analysed in R (version 2.14.2) [21], using packages rjags
(version 3–5) [22] and R2jags (version 0.03-06) [23].
Posterior distributions were simulated based on unin-
formative prior distributions (normal distributions with
mean 0 and standard deviation 100 for parameter means;
inverse gamma distributions with mean 1 and variance
10,000 for parameter variances; inverse scaled Wishart
distribution for the variance-covariance matrix of random
effects). Bayesian credible intervals (BCI) for parameter
estimates were based on the 2.5% and 97.5% percentiles
of posterior distributions. Posterior distributions were
simulated by means of four Markov chains, each con-
sisting of 1 million Monte Carlo samples (saving only
every 50th sample). The first half of all samples was
discarded for burn-in, allowing the model to converge.
Model convergence was assessed according to Gelman
and Rubin’s convergence diagnostic, the potential scale
reduction factor [24].
Differences are stated significant, based on the calcu-
lated 95% BCI. In the results section, significant differ-
ences are quantified by percentages. Not all significant
differences are quantified in the results section. An over-
view of all data and the corresponding 95% BCI’s is given
in an Additional file 1, annexed to the manuscript.
Results
Oligosaccharide fractions dose-dependently modulate
TNF-α production in unchallenged PBMCs
In Table 2, TNF-α and IL-10 production is illustrated
after incubation of PBMCs with oligosaccharide fractions
(including blank controls). All fractions significantly
increased TNF-α production by PBMCs compared to
blank controls and did so at all concentrations. Dose-
dependent effects were seen for all three oligosaccharide
fractions. For GOS, the dose-dependent increase was
only significant after incubation with 2% GOS compared
to incubation with 1% GOS (43% increase). For GOS/FOS, the dose-dependent increase of TNF-α production
was significant through the whole concentration range
(1% vs. 0.5%: 110% increase, 2% vs. 1%: 101% increase).
For GOS/FOS/AOS, a significant increase of TNF-α pro-
duction was evident when comparing the 1% incubation
with the 0.5% incubation (81% increase). In contrast,
PBMCs incubated with 2% GOS/FOS/AOS produced sig-
nificantly lower amounts of TNF-α compared to PBMCs
incubated with 1% GOS/FOS/AOS (54% reduction).
Production of IL-10 in unchallenged PBMCs was not
significantly influenced by oligosaccharide fractions in
comparison with blank controls.Oligosaccharide fractions dose-dependently modulate
cytokine production in LPS challenged PBMCs
Table 3 illustrates TNF-α and IL-10 production in LPS
challenged PBMCs after pre-incubation and co-incubation
with the applied oligosaccharide fractions (including incu-
bations with LPS alone). The TNF-α response in PBMCs
incubated with LPS alone was significantly increased
with 13,793% (138-fold) in comparison with blank
controls. Incubation with 0.5% solutions of all three
oligosaccharide fractions resulted in significantly higher
TNF-α concentrations compared to incubation with
LPS alone. A dose-dependent increase of TNF-α pro-
duction was observed for GOS and GOS/FOS within
the entire concentration range. When comparing 1%
incubations with 0.5% incubations, the increase of
TNF-α production was 36% for GOS and 53% for
GOS/FOS. For GOS, incubation with 2% solutions
resulted in an additional significant increase of TNF-α
production compared to 1% solutions (55% increase),
whereas for GOS/FOS this increase was not significant.
In contrast to GOS and GOS/FOS, incubation with
increasing concentrations of GOS/FOS/AOS resulted
in a dose-dependent reduction of TNF-α production in
LPS challenged PBMCs (1% vs. 0.5%: 22% reduction;
2% vs. 1%: 69% reduction). Moreover, TNF-α production
in LPS challenged PBMCs incubated with GOS/FOS/AOS
2% was significantly lower compared to incubation with
LPS alone (41% reduction).
The IL-10 response in PBMCs incubated with LPS
alone was significantly increased with 49% in compari-
son with blank controls. Whereas both GOS and GOS/
FOS incubations did not significantly alter the IL-10 re-
sponse following LPS stimulation, incubation with LPS
and GOS/FOS/AOS 0.5% did increase IL-10 production
significantly in comparison with incubation with LPS
alone (35% increase). Incubation with higher concentra-
tions of GOS/FOS/AOS resulted in a dose-dependent re-
duction of the LPS induced IL-10 response in PBMCs (1%
vs. 0.5%: 28% reduction, 2% vs. 1%: 33% reduction). More-
over, IL-10 production in LPS challenged PBMCs
Table 2 TNF-α and IL-10 production in unchallenged PBMCs incubated with oligosaccharide fractions
TNF- α (pg/ml) IL-10 (pg/ml)
Incubation Point estimate Lower bound Upper bound Point estimate Lower bound Upper bound
Blank controls 12.6 9.8 15.7 187.2 156.2 222.5
GOS 0.5% 19.7 * 16.5 23.3 183.1 152.8 217.7
GOS 1.0% 24.9 * 21.1 29.3 184.2 153.5 219.2
GOS 2.0% 35.5 *# 30.2 41.6 179.8 149.6 214.2
GOS/FOS 0.5% 30.2 * 25.7 35.4 185.5 154.8 221.4
GOS/FOS 1.0% 63.4 *# 54.1 74.2 190.2 160.0 225.7
GOS/FOS 2.0% 127.5 *# 108.6 149.5 186.0 154.5 221.4
GOS/FOS/AOS 0.5% 73.6 * 62.9 86.4 205.2 173.8 242.5
GOS/FOS/AOS 1.0% 133.5 *# 113.7 156.6 214.2 181.6 252.4
GOS/FOS/AOS 2.0% 61.4 *# 52.4 72.2 186.8 157.3 221.0
Mean protein concentrations of TNF-α and IL-10 (pg/ml) and 95% Bayesian Credible Intervals for unchallenged PBMCs incubated with oligosaccharide fractions
(including blank controls). Significant differences between oligosaccharide fractions and blank controls are marked with an asterisk (*) Significant dose-dependent
differences (1.0% vs. 0.5% and 2.0% vs. 1.0%) are marked with a hash (#).
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compared to incubation with LPS alone (35% reduction).
Oligosaccharide fractions affect the TNF-α response
significantly more profoundly compared to mono- and
disaccharide controls
To account for the mono- and disaccharide contents of
the applied oligosaccharide preparations, effects of these
oligosaccharide preparations were compared with effects
of corresponding glucose/lactose concentrations in the
same model. A comparison of the effects of oligosac-
charide preparations and glucose/lactose controls on the
TNF-α response in unchallenged PBMCs is given in
Figure 1.
Incubation of PBMCs with medium containing glucose
and lactose resulted in significantly higher TNF-α produc-
tion in comparison with blank controls (increase of 53%,
97%, and 84% for glucose/lactose solutions resemblingTable 3 TNF-α and IL-10 production in LPS challenged PBMCs
TNF- α (pg/ml)
Incubation Point estimate Lower bound Up
LPS 1 μg/ml 1749.4 1495.2 205
LPS + GOS 0.5% 3655.5 * 3115.0 428
LPS + GOS 1.0% 4989.0 *# 4251.4 584
LPS + GOS 2.0% 7754.3 *# 6607.8 909
LPS + GOS/FOS 0.5% 3601.1 * 3074.8 422
LPS + GOS/FOS 1.0% 5530.3 *# 4712.6 648
LPS + GOS/FOS 2.0% 6721.1 * 5733.0 787
LPS + GOS/FOS/AOS 0.5% 4242.9 * 3608.3 496
LPS + GOS/FOS/AOS 1.0% 3317.6 *# 2832.7 389
LPS + GOS/FOS/AOS 2.0% 1029.7 *# 874.8 120
Mean protein concentrations of TNF-α and IL-10 (pg/ml) and 95% Bayesian Credible
(including incubations with LPS alone). Significant differences between oligosaccha
dose-dependent differences (1.0% vs. 0.5% and 2.0% vs. 1.0%) are marked with a h0.5%, 1% and 2% GOS, respectively). However, no signifi-
cant dose-dependent effects were detected among the
glucose/lactose incubations.
A comparison with the GOS incubations revealed that
incubation of unchallenged PBMCs with 2% GOS
resulted in significantly more TNF-α production com-
pared to the corresponding glucose/lactose controls (52%
increase), whereas effects of the 0.5% and 1% GOS and
corresponding glucose lactose incubations did not differ
significantly. For GOS/FOS and GOS/FOS/AOS, all ef-
fects on TNF-α production were significantly more
profound compared to the effects of corresponding
glucose/lactose controls.
Effects of oligosaccharide preparations and glucose/
lactose controls on the TNF-α response in LPS chal-
lenged PBMCs are compared in Figure 2. Whereas incu-
bation of PBMCs with glucose/lactose resembling 0.5%
GOS did not alter LPS induced TNF-α productionincubated with oligosaccharide fractions
IL-10 (pg/ml)
per bound Point estimate Lower bound Upper bound
0.8 278.1 236.0 328.7
5.5 293.8 248.4 347.6
3.0 268.8 227.5 316.7
0.6 265.6 225.0 313.6
1.7 344.1 290.9 407.5
3.4 307.4 260.6 362.9
9.3 264.0 223.9 311.7
9.1 374.3 * 317.0 442.3
3.3 269.6 # 227.9 318.3
5.9 180.7 *# 149.0 216.6
Intervals for LPS challenged PBMCs incubated with oligosaccharide fractions
ride fractions and LPS alone are marked with an asterisk (*). Significant
ash (#).
Figure 1 Comparison of the effects of oligosaccharide fractions vs. glucose/lactose controls on TNF-α response in unchallenged
PBMCs. Relative TNF-α production compared to blank controls and 95% Bayesian Credible Intervals are given for all investigated incubations,
including glucose/lactose controls (glucose/lactose ‘x%’ meaning corresponding with glucose/lactose concentrations of x% GOS). Significant
differences are marked with lower case letters. a: Significant difference between oligosaccharide or glucose/lactose fractions and blank controls.
b: Significant difference between oligosaccharide fractions and corresponding glucose/lactose controls.
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with 1% and 2% GOS enhanced the LPS induced TNF-α
production dose-dependently (1% vs. 0.5%: 24% increase;
2% vs. 1%: 42% increase).
Differences between effects of the applied oligosac-
charide preparations and glucose/lactose controls wereFigure 2 Comparison of the effects of oligosaccharide fractions vs. gl
PBMCs. Relative TNF-α production compared to PBMCs incubated with 1 μ
investigated incubations, including glucose/lactose controls (glucose/lactos
x% GOS). Significant differences are marked with lower case letters. a: Signi
and LPS alone. b: Significant difference between oligosaccharide fractions aevident through the entire concentration range. For all
investigated GOS and GOS/FOS concentrations, TNF-α
production was significantly higher after incubation with
the oligosaccharide fraction compared to the correspon-
ding glucose/lactose concentrations. In contrast, for
GOS/FOS/AOS a dose-dependent decrease in TNF-αucose/lactose controls on TNF-α response in LPS challenged
g/ml LPS and 95% Bayesian Credible Intervals are given for all
e ‘x%’ meaning corresponding with glucose/lactose concentrations of
ficant difference between oligosaccharide or glucose/lactose fractions
nd corresponding glucose/lactose controls.
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bated with GOS/FOS/AOS 2% produced significantly
less TNF-α compared to corresponding glucose/lactose
controls (71% reduction).
A comparison of the effects of oligosaccharide prepara-
tions and corresponding glucose/lactose concentrations
on IL-10 production could not be executed, as IL-10
concentrations which were measured in the glucose/lac-
tose experiments were mostly below the detection limit
of the ELISA.Incubation of PBMCs with GOS/FOS/AOS significantly
enhances cell viability
Results for the CCK-8 viability assays are illustrated in
Figure 3. The investigated incubations did not signifi-
cantly reduce cell viability compared to blank controls.
However, all investigated GOS/FOS/AOS incubations
significantly increased the apparent cell viability (ranging
from 38-61% increase). Besides this, a mild (14%) but
significant increase of cell viability was observed for
glucose/lactose concentrations resembling 1% GOS.Minor endotoxin contamination of the applied
oligosaccharide fractions
According to the performed bioassay, all oligosaccharide
solutions contained measurable concentrations of endo-
toxin. For the 2% solutions, the endotoxin concentra-
tions (mean values ± standard deviation) were estimated
at 0.24 ± 0.02 EU/ml (GOS), 1.06 EU/ml (GOS/FOS,
based on measurements in 1% solution: 0.53 ± 0.07 EU/
ml) and 1.92 EU/ml (GOS/FOS/AOS, based on mea-
surements in 1% solution: 0.96 ± 0.07 EU/ml). The glu-
cose and lactose solutions did not contain measurable
amounts of endotoxin (lower detection limit of the assay
was 0.1 EU/ml).Figure 3 Results for the CCK-8 viability assay. Cell viability is given for a
blank controls, including 95% Bayesian Credible Intervals. Significant increaDiscussion
Individual oligosaccharides exhibit distinct
immunomodulatory properties
Based on our results, we can conclude that both GOS
and GOS/FOS fractions dose-dependently enhanced the
pro-inflammatory response by LPS challenged equine
PBMCs. In contrast, after incubation with 2% GOS/
FOS/AOS the LPS induced inflammatory response was
dose-dependently reduced. This indicates that with in-
creasing the AOS concentration in the incubations, the
stimulatory effects of both GOS and GOS/FOS were
eventually overruled by the suppressive effects of AOS
in this model. Suppression of the cytokine response was
not caused by cytotoxic properties of AOS. On the con-
trary, PBMC viability was significantly increased in all
GOS/FOS/AOS incubations compared to blank incuba-
tions, suggesting a protective or mitogenic effect. In
conclusion, the reduced cytokine production by PBMCs
incubated with GOS/FOS/AOS was not the result of a
reduced number of viable cells, as lower amounts of
cytokines were produced by a higher number of cells.
We cannot exclude that a direct interaction between
AOS and LPS influenced the LPS response in PBMCs
incubated with GOS/FOS/AOS. Binding of LPS by AOS
in the gut lumen might even contribute to the docu-
mented beneficial effects of oligosaccharide fractions
containing AOS in in vivo studies.
Though we observed modulatory effects of mono- and
disaccharides on the LPS induced inflammatory response
in our model, these effects were less pronounced and
overshadowed by the immunomodulating effects of the
investigated oligosaccharide fractions. To our know-
ledge, literature regarding the underlying mechanism of
action of mono- and disaccharides, which enhance the
LPS induced inflammatory response, is lacking. How-
ever, our results are in line with a recently publishedll investigated incubations, relative to cell viability as determined in
ses of cell viability are marked with an asterisk (*).
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enhance the TNF-α and IL-6 response following LPS
challenge [25].
Endotoxin contamination is not responsible for the
enhancement of the LPS response by oligosaccharide
fractions
As PBMCs are extremely sensitive to bacterial endo-
toxin, it cannot be excluded that the significant increase
of TNF-α production in unchallenged PBMCs after in-
cubation with the applied oligosaccharide fractions was
caused by the low endotoxin concentrations in these
natural products. Although it is not possible to give an
exact concentration based on the results obtained with
the Limulus assay, it can be assumed that the degree of
endotoxin contamination ranged from 1.20- 19.20 ng/ml
for the 2% oligosaccharide solutions. This estimate is
based on the information of the manufacturerc of the
applied LPS (1 ng LPS = 5–10 EU). We challenged the
PBMCs with 1000 ng/ml LPS, as preliminary experi-
ments with this PBMC model indicated that this
concentration already results in a maximum TNF-α re-
sponse after 4 hours of incubation. As 1.20- 19.20 ng/ml
is almost negligible compared to a concentration of
1000 ng/ml, it can be assumed that this low endotoxin
contamination cannot be held accountable for the en-
hancement of the LPS response by the oligosaccharide
fractions in our model. Moreover, the enhancement of
the TNF-α response in LPS challenged cells was not pro-
portional to the mild stimulatory effects in unchallenged
PBMCs.
However, endotoxin contamination might play a role
in the reduction of the LPS response after incubation
with 2% GOS/FOS/AOS. In this solution, the measured
endotoxin concentration was the highest (approximately
10–19 ng/ml) and we cannot exclude that endotoxin
tolerance was induced during the PBMC pre-incubation
period, suppressing the response after the actual chal-
lenge [26]. On the other hand, the 1% solution of GOS/
FOS/AOS (approximately 5–10 ng/ml endotoxin) al-
ready caused a significant reduction of the LPS response
in comparison with the 0.5% GOS/FOS/AOS solution,
whilst the 2% GOS/FOS solution (approximately 6–
11 ng/ml endotoxin) induced a significant increase of
the LPS response compared with the 1% GOS/FOS so-
lution. Hence, distinct modulatory effects of the AOS
fraction remain plausible.
Direct effects of oligosaccharides
Previously performed in vivo studies often ascribe im-
munomodulatory effects of dietary oligosaccharides to
their prebiotic properties. However, the results of this
study support the hypothesis of direct modulatory
effects of oligosaccharides, independent of the intestinalmicro biota. Though this notion is also supported by
other in vitro studies [16,17], the method of action
behind direct immunomodulation by oligosaccharides
remains unclear. Carbohydrate (glycan)- binding recep-
tors expressed on the surface of intestinal epithelial cells
and antigen presenting cells may be involved in modula-
tion of the immune response by sugar molecules [27]. In
addition, next to modulation of Toll-like receptor (TLR)
signalling in the gastrointestinal tract due to the changes
in the gut flora, oligosaccharides may directly modulate
TLR- signalling. For instance, hyaluronan oligosaccha-
rides have been shown to directly mediate inflammatory
responses via TLR-4 [28,29]. As known TLR-4 ligands
such as LPS display structural similarity with the investi-
gated oligosaccharides, other oligosaccharides may influ-
ence TLR-4 signalling as well.
As of yet, research with oligosaccharides mainly in-
volved direct intervention studies in human infants or in
experimental (rodent) animal species as surrogates for
human infants [6-15]. One in vivo study in adult horses
demonstrated beneficial effects of prebiotic short-chain
fructo-oligosaccharides, preventing disruption of the in-
testinal flora in the equine hindgut in case of an abrupt
change of diet composition [30]. Concerning immuno-
modulation by oligosaccharides in the horse, no data have
been published to our knowledge. The data obtained
from the present study confirm the activity of heterol-
ogous oligosaccharides in horses and are in line with
the very few published in vitro studies with human cell
culture models [16,17].
The most notable finding was the divergence between
the immuno-activation of PBMCs by GOS and GOS/
FOS preparations and the apparent suppressive effect of
AOS. This was an unexpected outcome and indicates
that forthcoming experimental protocols should include
conditions with AOS only. In the current experiments
we applied the (commercially available) combinations of
oligosaccharides used in previous studies, and hence
AOS was not tested separately.
Conclusions
In conclusion, this study provides evidence that oligosac-
charides from different sources have distinct direct im-
munomodulatory properties. We showed that both GOS
and FOS dose-dependently stimulated the LPS induced
inflammatory response in equine PBMCs, and that AOS
dose-dependently suppressed the production of both
TNF-α and IL-10 following an LPS challenge. Such an
activation or suppression of the immune system could
be beneficial in vivo, depending on the clinical context.
Future research into dietary supplementation of specific
oligosaccharide fractions in foals and underlying immu-
nomodulatory mechanisms could lead to the develop-
ment of oligosaccharide supplements in foals, to support
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first phase of life, hence protecting them from early,
often life-threatening infections.
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